UPDATE: The International NUT Carcinoma Diagnosis and Treatment Center officially opened today, January 29, 2026, at Boao International Hospital, marking a significant breakthrough in the fight against NUT carcinoma, a rare and aggressive cancer. This urgent initiative is a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, aimed at addressing the critical challenges faced by patients suffering from this deadly disease.
NUT carcinoma is notoriously difficult to diagnose and treat, contributing to a grim prognosis for patients. However, the new center is introducing NHWD-870, a groundbreaking oral BET inhibitor developed by Zhejiang Wenda Pharma Technology Co., Ltd.. Clinical trials for NHWD-870 have shown promising results, with an objective response rate of 33.3% and a disease control rate of 73.33%. Most notably, this innovative treatment has extended the median overall survival for patients to 9.3 months, with real-world studies reporting a one-year survival rate of 54.7%.
“Our mission is to light a definitive beacon of hope,” stated Professor YIN Mingzhu, a leading figure at the center. “We are here to ensure every patient has access to advanced, life-extending care.” This statement underscores the center’s commitment to transforming the lives of those affected by NUT carcinoma.
Strategically located in the Boao Hope Pilot Zone of International Medical Tourism, the center benefits from unique policies that permit rapid introduction of global innovations and expedite domestic breakthroughs such as NHWD-870. This zone has already introduced over 540 innovative therapies, establishing itself as a vital gateway for medical advancements in China.
The International NUT Carcinoma Center will not only provide treatment but also serve as a global hub for cutting-edge clinical trials and research. This initiative builds on the legacy of Chongqing University Three Gorges Hospital, which pioneered China’s first dedicated NUT carcinoma clinic and has treated over 200 patients nationwide. Their leadership in developing the nation’s first expert consensus on NUT carcinoma sets a strong foundation for this new center.
In addition to NHWD-870, Zhejiang Wenda is advancing multiple drug candidates through clinical trials, focusing on oncology and other serious diseases. The company is dedicated to developing safer, more effective treatment options for patients facing refractory and incurable diseases.
The launch of the International NUT Carcinoma Center represents a pivotal moment in the fight against this rare cancer. As the center begins to operate, it aims to change the narrative for NUT carcinoma and provide much-needed hope for patients and their families.
Stay tuned for further updates as this groundbreaking center begins to impact lives and reshape treatment standards for NUT carcinoma globally.
